Regencell Bioscience Holdings (RGC) Current Leases (2022 - 2025)

Regencell Bioscience Holdings' (RGC) quarterly Current Leases came in at $258124.0 in Q4 2025, down 17.47% on a QoQ basis from $312780.0 in Q2 2025.

Regencell Bioscience Holdings (RGC) Current Leases (2022 - 2025) Analysis & Trends

Regencell Bioscience Holdings (RGC) has 4 years of Current Leases data on file, last reported at $258124.0 in Q4 2025.

Quarterly Current Leases changed N/A year-over-year to $258124.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $258124.0 (changed N/A YoY) and the FY2025 annual result came in at $312780.0, up 422.98% from the prior year.
Current Leases retreated to $258124.0 in Q4 2025, from $312780.0 in the prior quarter.
In the past five years, Current Leases ranged from a high of $438263.0 in Q2 2023 to a low of $59807.0 in Q2 2024.
A 4-year average of $295992.2 and a median of $312780.0 in 2025 frame the typical range for Current Leases.
Annual changes were most pronounced in 2024 — Current Leases slumped 86.35% — and 2025, when it surged 422.98%.
Tracing RGC's Current Leases over 4 years: stood at $410987.0 in 2022, then grew by 6.64% to $438263.0 in 2023, then tumbled by 86.35% to $59807.0 in 2024, then soared by 331.59% to $258124.0 in 2025.
The last three Current Leases figures came in at $258124.0 (Q4 2025), $312780.0 (Q2 2025), and $59807.0 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	-
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Regencell Bioscience Holdings	2.67 Bn	2.67 Bn	-	258,124.00

Download Data